CN1108537A - Treatment of dermatitis of housewife - Google Patents
Treatment of dermatitis of housewife Download PDFInfo
- Publication number
- CN1108537A CN1108537A CN94104807.1A CN94104807A CN1108537A CN 1108537 A CN1108537 A CN 1108537A CN 94104807 A CN94104807 A CN 94104807A CN 1108537 A CN1108537 A CN 1108537A
- Authority
- CN
- China
- Prior art keywords
- sulfur
- salicylic acid
- dermatitis
- salicylic
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 27
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 58
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 32
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 230000002195 synergetic effect Effects 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 150000002148 esters Chemical class 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 239000011593 sulfur Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000003203 everyday effect Effects 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940016409 methylsulfonylmethane Drugs 0.000 abstract 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 239000006071 cream Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005336 cracking Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 101150102923 MSM1 gene Proteins 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007788 roughening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to synergistic compositions comprising sulphur and salicylic acid or a physiologically acceptable salt or ester of salicylic acid and methylsulfonylmethane, and to their use in formulations and methods for the treatment and prevention of dermatitis on housewife and for the protection and improvement of skin conditions.
Description
Housewife dermatitis is a kind of very common disease, and it constantly causes the great interest of people.Because mechanism complexity and the challenging meaning of its treatment that it forms.This class disease has been represented the damage that the skin of finger and hands is suffered behind contact domestic detergent, cleaning agent and purificant.This class dermatitis shows as finger and hands self drying, coarse, thickening, splits.The stimulation that is exposed to sunlight, air pollutants and environment for a long time all can encourage such dermatitis and it is increased the weight of.
Housewife dermatitis is still a kind of disease that is difficult to treat, and purpose of the present invention is introduced a kind of effective therapy exactly, and this therapy not only can be eliminated these dermatitis, and can stop its recurrence.
The formation mechanism of housewife dermatitis is complicated.Although on market, can obtain a lot of medicines, but do not have a kind of can be in order to resist the pathological factor after this type of dermatitis forms, do not have yet a kind of can be to the medium of preventing skin damage and infringement, these media are represented prevailing approach, by these approach, stimulus object such as detergent have side effects to skin.Therefore, the present invention directly illustrates these viewpoints by a kind of synergistic compositions that has is provided.These compositionss can not only be treated housewife dermatitis and short its recovery from illness effectively, and can prevent the recurrence of this class disease.Be to use the present invention to improve the dermatosis symptom and keep skin texture and the description of vigor below.
The invention provides a kind of Synergistic compositions that is applicable to the treatment housewife dermatitis, said composition comprises sedimentary sulfur and salicylic acid and methanesulfonylmethawithin.
According to the present invention, wondrous and be surprised to find that very said composition is used for hand skin can improve basic disease in many ways, these modes comprise irritation, keep structure and vigor, especially prevent and treat housewife dermatitis.In addition, be also noted that this compositions has good adhesiveness to skin, therefore the contact of long period can be provided and promote treatment to discharge.And, be interactional between the component of said composition in the synergism mode, promptly the effect sum of the each component that uses respectively is lower than the shown effect of said composition.
For further improving the useful effect of said composition, comprise also that wherein a kind of vasodilation (for example menthol) is favourable to skin.
On the other hand, the invention provides a kind of can with the mixed uniformly compositions of a kind of physiology acceptable carrier, to be used to improve the hand skin situation.
On the other hand, the invention provides a kind of topical preparation, said preparation comprise a kind of can with the mixed uniformly mixture of a kind of pharmaceutically acceptable excipient.This type of excipient should be " can accept ", and promptly normally to being treated the harmless class of skin, they can be compatible with other component in the preparation for meaning.Certainly should be understood that some patient has the obvious more responsive skin than the ordinary people, therefore at these in particular cases, the selectivity excipient that generally is used for these people should be tried.
Suitable excipient is well known in the art, these type of standard substance as mentioning in British Pharmacopoeia and the Britain's country's codes (British National Formulary) comprise ointment base and white base and washing liquid, paste, gel, spray, aerosol and bath oil.Ointment and cream can comprise the colloidal state soil of oils and fats adsorptivity, thickening agent such as tragacanth gum or sodium alginate and other pharmaceutically useful additional ingredients such as wetting agent, antiseptic, buffer agent and antioxidant, and they are useful in this type of prescription.
General cream dosage form preferably is because they are to be the most receptible form of most of user.A kind of substrate especially easily is to use the polyethyleneglycol cetyl ether, it for example comprise newly boil and refrigerative purified water in, the 30%W/V polyethyleneglycol cetyl ether oil emulsion unguentum (the polyethyleneglycol cetyl ether emulsifing wax of 30%W/W, 20%W/W liquid paraffin, 50%W/W white soft paraffin) that contains 0.1%W/V chlorocresol for example or 0.08%W/V propyl salicylate, 0.15%W/V methyl salicylate and 1.5%W/V benzyl alcohol.
Usually, the various active ingredients that compositions of the present invention contains account for 0.5%W/W at least, preferably from 1 to 20%W/W, and most preferably 2 to 10%W/W.Yet these dosage do not show that the relative ratios of active constituent should be certain.
Valuably, compositions of the present invention can be used the therapeutic effect that prolongs to obtain in excipient in the part of a kind of slow release or slow release.
The number of times of topical application is dependent on operation instruction.When treatment during dermatitis, on the skin of hands, wipe with the cream number of any amount minute 2 or 3 times on the one gently.Use reservation when advising is at dusk spent the night with the reparation of quickening skin injury and is urged its recovery from illness.To preventing housewife dermatitis or keeping the vigor of hand skin and prevent its drying or roughening and cracking, use once just enough every day as mentioned above.Before using next time, must wash off with the cream that warm water will be coated with last time.Must avoid this class medicament to contact with consumer goods with mouth with eye.
Though do not limit the scope of the invention, it is believed that the mechanism of action after the beneficial effect of this type of medicament is included in to have removed the deutero-free radical of cytotoxicity oxygen to a certain extent that this type free base has mediated tissue injury.
Following embodiment present invention will be further described other preferred characteristic and advantages are only described the present invention in the mode of explanation.
Embodiment 1-prepares the skin treating cream
A. methanesulfonylmethawithin 5g
Precipitated sulfur 4g
Salicylic acid 2g
Polyethyleneglycol cetyl ether ' A ' adds to 100g
B. methanesulfonylmethawithin 5g
Precipitated sulfur 4g
Salicylic acid 2g
Menthol crystallization 1g
Polyethyleneglycol cetyl ether ' A ' adds to 100g
Should prepare these compositionss down at 25 ℃.In glass or rustless steel container, powdered activated component is mixed fully, add the polyethyleneglycol cetyl ether ' A ' of Sq then and stirred 10 minutes.Should half when using menthol it at first pulverize.Said composition placed be placed in 1 hour in the dark dense glass container and deposit being no more than under 26 ℃.Must not use this cream at least 12 hours after having prepared, and should not make it after being exposed in the air for a long time or being subjected to the sunlight direct projection.
The local use of embodiment 2-with cream.
Use according to prevention or treatment, use embodiment 1 described preparation every day 1 to 3 time.For the skin of avoiding hands and finger is subjected to the damage that detergent and home-use reagent produce, keep its structure and prevent drying, advise usually using once every day.Be applied in hands or by on the skin of treatment place and massaged a few minutes gently with the cream of random amount.For therapeutic purposes, need use also preferably use between the lights and maintenance for the second time and spend the night.New medicament should be do not used during medicament washing last time off, only just medicament last time can be washed off with warm water.According to each case, especially existing skin of patient and demand, treatment can last for days or several weeks.
The detailed assessment of embodiment 3-compositions and active constituent thereof
The women that by diagnosis suffered from housewife dermatitis (pachylosis, the thickening of finger and hands and split) selected to (by extracting the envelope of sealing) in advance at random carries out double-blind trial, with different medicament (being present in polyethyleneglycol cetyl ether ' A ' substrate) or only treat with this substrate (matched group), study their curative effect, medicament is used twice every day, altogether, as shown in the table.Every set of dispense is 10 women study, and overall the range of age is 31 to 55 years old.Skin cracking recovery from illness by observing whole patients also is accompanied by skin texture and returns to initial smoothly, has estimated successful therapeutic outcome objectively.
Table: the therapeutic effect of housewife dermatitis
The successful treatment of treatment group (n=10)
The polyethyleneglycol cetyl ether ' A'0
Sulfur 1% 0
Sulfur 2% 0
Sulfur 5% 0
Sulfur 10% 0
Salicylic acid 1% 0
Salicylic acid 2% 0
Salicylic acid 5% 0
Salicylic acid 10% 0
Sulfur 1%+ salicylic acid 1% 10%
Sulfur 2%+ salicylic acid 2% 20%
Sulfur 5%+ salicylic acid 5% 30%
Sulfur 10%+ salicylic acid 10% 30%
MSM1% 10%
MSM2% 10%
MSM5% 30%
MSM10% 30%
MSM1%+ sulfur 1%+ salicylic acid 1% 40%
MSM2%+ sulfur 2%+ salicylic acid 2% 80%
MSM5%+ sulfur 5%+ salicylic acid 5% 100%
MSM10%+ sulfur 10%+ salicylic acid 10% 100%
MSM: methanesulfonylmethawithin
This result of study clearly illustrates that sulfur and salicylic acid all can not produce any useful therapeutic effect to housewife dermatitis, but then produces certain curative effect when they combine.In any case, increased to the adding concertedness of methanesulfonylmethawithin the gained curative effect.And this result has supported the selection as optimal dose that embodiment 1 adopts.
Embodiment 4-clinical trial
Selected at random in advance (by extracting the envelope of sealing) women is carried out double-blind trial to measure and its substrate (polyethyleneglycol cetyl ether ' A ') and the specific therapeutical of only using substrate (matched group) to compare.The treatment coding is only just made known when experimental period finishes.
A. measure the curative effect of the described preparation of embodiment 1.B to housewife dermatitis.Use secondary, totally six weeks every day during test.Housewife dermatitis be meant only be that the most skin of finger skin or hands thickens, roughening and cracking.26 women (the range of age 32 was to 55 years old-average 43 years old) that assign to matched group at random and 24 women (the range of age 35 was to 51 years old-average 42 years old) that assign to the treatment group have at random been carried out thoroughly evaluating.Though in matched group, do not produce useful curative effect, observed useful curative effect in whole active treatment groups (100%).The skin cracking of observing these women is returned to one's perfect health and has been recovered the smooth and original normal configuration and the outward appearance of its skin.
In any test example, all do not observe the effect of paying or allergy.
B has tested the mitigation of the described preparation of embodiment 1.A to women's symptom, and being tried women complaint has when they contact with detergent or other home-use chemicals and itch and the hyperesthesia phenomenon, but does not also have the manifest symptom of dermatitis.Between exposure period, use said preparation or its substrate, totally ten days twice of every day in hand.20 reference examples (the range of age 32 years old to 51 years old-average 40 years old) and 21 treatment examples (the range of age 31 years old to 49 years old-average 38 years old) have been carried out thoroughly evaluating.The symptom of all active treatment examples (100%) is all alleviated, but does not have in matched group.Side reaction, allergy or anaphylaxis all do not take place in all active treatment.
C. observed embodiment 1.B described preparation preventive effect after successfully treating housewife dermatitis to its recurrence.Instruct all women to resemble them and continue their daily housework before seeking dermatitis in treatment, and guide them to use the hands frost to maintain, and make its reservation spend the night and wash off with warm water at m seq.Treatment continues four months (research end point).23 women (the range of age 31 was to 51 years old-average 36 years old) to 25 women in the matched group (the range of age 28 was to 54 years old-average 39 years old) and active treatment group have carried out thoroughly evaluating.In whole active treatment groups (100%), observe the recurrence that has prevented housewife dermatitis fully and kept the smooth and normal skin texture of hands, but in matched group, do not observe.
Time-delay is used all patients that can not produce part or systemic side effect and can be accepted research and is well tolerated.
Embodiment 5-toxicity research
Healthy male volunteer at 18 to 40 years old studies to the age, and one group of ten people prepare series preparation down with polyethyleneglycol cetyl ether ' A ' substrate that describes in detail as embodiment 1:
1, methanesulfonylmethawithin 1%+ sulfur 1%+ salicylic acid 1%
2, methanesulfonylmethawithin 2%+ sulfur 2%+ salicylic acid 2%
3, methanesulfonylmethawithin 5%+ sulfur 5%+ salicylic acid 5%
4, methanesulfonylmethawithin 10%+ sulfur 10%+ salicylic acid 10%
5, methanesulfonylmethawithin 15%+ sulfur 15%+ salicylic acid 15%
Use these preparations twice, totally ten days every day on shoulder and arm.During each the application, the cream of arbitrarily measuring is coated on shoulder and the arm, massaged gently several minutes then.After three hours, wash off with warm water.During research in ten days, carry out physical examination every day one time.Equally, carry out conventional hematology and biochemical test (comprising liver and renal function test, blood glucose, serum amylase and vim and vigour (blood gases)) with urine every day.Measure the electrocardiogram of an assess cardiac enzyme level every other day.
All therapeutic doses all can comfortable tolerances and can not produced any obvious allergy or side effect.In addition, use any dosage also can toxigenicity.Therefore, can conclude that it is safe that embodiment 1 described preparation is used for clinical with recommended doses.
Though should be understood that the sulfur and salicylic acid and the methanesulfonylmethawithin that in Synergistic compositions of the present invention, adopt identical weight usually, also can use other ratio.General commonly used ratio is from 30: 1 to 1: 10, preferably from 15: 1 to 1: 5, most preferably from 3: 1 to 1: the 1(weight ratio).
And sulfur and salicylic relative scale can change, and be for example between 10: 1 and 1: 5, preferred 5: 1 to 1: 1, favourable greatly about 2: 1.
For avoiding producing query, should know that term " housewife dermatitis " is not to be used for indicating the particular sex conditioned disjunction purposes and the therapy of the present invention of these compositionss is limited to the women.
Claims (12)
1, a kind of Synergistic compositions, said composition contain sulfur and salicylic acid or salicylic physiological acceptable salt or ester and methanesulfonylmethawithin.
2, according to the compositions of claim 1, the weight ratio of wherein said sulfur and salicylic acid or salicylic physiological acceptable salt or ester and methanesulfonylmethawithin is from 15: 1 to 1: 5.
3, according to the compositions of claim 1 or 2, wherein said sulfur and salicylic weight ratio are from 10: 1 to 1: 5.
4, according to the compositions of arbitrary claim of claim 1 to 3, wherein said sulfur is the form of precipitated sulfur.
5, a kind of compositions that is used to prepare treatment and prevents the preparation of housewife dermatitis, it contains sulfur and salicylic acid or salicylic physiological acceptable salt or ester and methanesulfonylmethawithin.
6, a kind of preparation that is used to improve skin, it comprises the compositions that can accept arbitrary claim of the mixed uniformly claim 1 to 4 of carrier with physiology.
7, according to the topical preparation of claim 6, it contains and at least respectively is the sulfur of 0.5%W/W and salicylic acid or salicylic physiological acceptable salt or ester and methanesulfonylmethawithin.
8, according to the preparation of claim 7, it contains respectively is 1 to 20%W/W sulfur and salicylic acid or salicylic physiological acceptable salt or ester and methanesulfonylmethawithin.
9, the method for a kind of prevention or treatment housewife dermatitis, it comprises the preparation of the claim 6 of using effective dose.
10, a kind of method of protecting and improving skin condition shape, it comprises the preparation of the claim 6 of using effective dose.
11, according to the method for claim 9 or 10, wherein the topical preparation with claim 7 is applied to skin.
12, according to the method for claim 11, wherein topical preparation is applied to skin, every day at least twice.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929218771A GB9218771D0 (en) | 1992-09-04 | 1992-09-04 | Synergistic composition for dermatitis treatment |
| PCT/GB1993/001874 WO1994005302A1 (en) | 1992-09-04 | 1993-09-03 | Dermatitis treatment compositions containing sulphur, salicylic acid and a sulphydryl group releasing agent |
| AU49745/93A AU4974593A (en) | 1992-09-04 | 1993-09-03 | Dermatitis treatment compositions containing sulphur, salicylic acid and a sulphydryl group releasing agent |
| CN94104807.1A CN1108537A (en) | 1992-09-04 | 1994-03-16 | Treatment of dermatitis of housewife |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929218771A GB9218771D0 (en) | 1992-09-04 | 1992-09-04 | Synergistic composition for dermatitis treatment |
| CN94104807.1A CN1108537A (en) | 1992-09-04 | 1994-03-16 | Treatment of dermatitis of housewife |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1108537A true CN1108537A (en) | 1995-09-20 |
Family
ID=36954586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94104807.1A Pending CN1108537A (en) | 1992-09-04 | 1994-03-16 | Treatment of dermatitis of housewife |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN1108537A (en) |
| AU (1) | AU4974593A (en) |
| GB (1) | GB9218771D0 (en) |
| WO (1) | WO1994005302A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681852A (en) * | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
| US5821237A (en) * | 1995-06-07 | 1998-10-13 | The Procter & Gamble Company | Compositions for visually improving skin |
| US5645825A (en) * | 1995-06-07 | 1997-07-08 | The Procter & Gamble Company | Depilatory compositions comprising sulfhydryl compounds |
| US5683705A (en) * | 1996-03-29 | 1997-11-04 | Estee Lauder, Inc. | Sulfur-based amides and bis-amides useful against skin disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK103797C (en) * | 1963-05-01 | 1966-02-21 | Barnes Hind Lab Inc | Cosmetic. |
| JPS58198421A (en) * | 1982-05-14 | 1983-11-18 | Reiko Kosaka | Composition for decoloring skin and treating skin disease |
| GB8517299D0 (en) * | 1985-07-09 | 1985-08-14 | Salim A S M | Dermatologically active substances |
-
1992
- 1992-09-04 GB GB929218771A patent/GB9218771D0/en active Pending
-
1993
- 1993-09-03 AU AU49745/93A patent/AU4974593A/en not_active Abandoned
- 1993-09-03 WO PCT/GB1993/001874 patent/WO1994005302A1/en active Application Filing
-
1994
- 1994-03-16 CN CN94104807.1A patent/CN1108537A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994005302A1 (en) | 1994-03-17 |
| AU4974593A (en) | 1994-03-29 |
| GB9218771D0 (en) | 1992-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100347651B1 (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| Galbraith | Treatment of acute herpes zoster with amantadine hydrochloride (Symmetrel) | |
| CA2408541C (en) | Treating eczema and/or psoriasis | |
| US6613800B1 (en) | Method and compositions for treating psoriasis, eczema, seborrhea and arthritis | |
| AU2001260833A1 (en) | Treating eczema and/or psoriasis | |
| JPH08505388A (en) | Hyaluronic acid-urea pharmaceutical composition and use thereof | |
| CA2255681C (en) | Composition and method for treating herpes simplex | |
| US8586064B2 (en) | Treating eczema and/or psoriasis | |
| CN1108537A (en) | Treatment of dermatitis of housewife | |
| US20060205699A1 (en) | Topical treatment for psoriasis | |
| CN106236612A (en) | A kind of toothpaste and preparation method thereof | |
| GB2177918A (en) | Pharmaceutical compositions containing procaine | |
| CN1055392C (en) | Psoriasis treatment | |
| CN1108538A (en) | synergistic composition for treating dermatitis | |
| CN1393221A (en) | Liquid medicine for treating acne | |
| WO1994005301A1 (en) | Dermatitis treatment compositions containing sulphur, salicylic acid and dimethylsulphone | |
| RU2132187C1 (en) | Method and magnetic active organic iron compound for treating skin and mucosa disease | |
| SU1395328A1 (en) | Method of treatment of diffusion neurodermite | |
| SIMPSON et al. | Vitamin D in the treatment of acne | |
| FI119101B (en) | Magnesium salts conditioner for the treatment of tumors or the like and use of magnesium sulfate | |
| RU2171682C1 (en) | Ointment for treatment of patients with psoriasis | |
| EP2192912B1 (en) | Essential oil of kunzea ambigua and methods of use | |
| EP2849742A1 (en) | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy | |
| NZ522434A (en) | Treating eczema and/or psoriasis | |
| JPH0449238A (en) | Skin disease therapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |